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Background: Myostatin is a protein synthesized and secreted by skeletal muscle that negatively regulates muscle
mass. The extent to which circulating myostatin levels change in the context of aging is controversial, largely due
to methodological barriers.
Methods: We developed a specific and sensitive liquid chromatography with tandem mass spectrometry (LC-MS/
MS) assay to measure concentrations of myostatin and two of its key inhibitors, follistatin-related gene (FLRG) protein
and growth and serum protein-1 (GASP-1) in 80 younger (<40 years), 80 older (>65 years), and 80 sarcopenic older
women and men.
Results: Older women had 34 % higher circulating concentrations of myostatin than younger women. Per unit of lean
mass, both older and sarcopenic older women had >23 % higher myostatin levels than younger women. By contrast,
younger men had higher myostatin concentrations than older men with and without sarcopenia. Younger men had
approximately twofold higher concentrations of myostatin than younger women; however, older women and
sarcopenic older women had significantly higher relative myostatin levels than the corresponding groups of men. In
both sexes, sarcopenic older subjects had the highest concentrations of FLRG. Circulating concentrations of myostatin
exhibited positive, but not robust, correlations with relative muscle mass in both sexes.
Conclusions: Our data suggest that myostatin may contribute to the higher prevalence of sarcopenia in women but
acts as a homeostatic regulator of muscle mass in men. Moreover, this new LC-MS/MS-based approach offers a means
to determine the extent to which myostatin serves as a biomarker of muscle health in diverse conditions of muscle loss
and deterioration.
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Over 50 years ago, circulating tissue-specific growth in-
hibitors were hypothesized to explain how tissue sizes
are controlled [1]. Considerable work has since estab-
lished growth and differentiation factor (GDF)-8, or
myostatin, as a robust negative regulator of skeletal
muscle mass. Myostatin is a member of the transforming* Correspondence: lebrasseur.nathan@mayo.edu
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creativecommons.org/publicdomain/zero/1.0/growth factor β (TGF-β) superfamily that is highly
enriched in skeletal muscle [2]. It is synthesized as a pre-
cursor protein and forms a disulfide-linked homodimer.
The signal peptide of the myostatin precursor protein is
removed by proteolytic cleavage to form promyostatin
[2, 3]. Furin protein convertases within the Golgi appar-
atus or the extracellular space cleave promyostatin to
generate N- and C-terminal fragments [4, 5], which are
bound non-covalently and form a latent myostatin com-
plex. The N-terminal is an inhibitory prodomain, referred
to as propeptide, and the C-terminal represents the ma-
ture biologically active form of myostatin. The latent com-
plex is disassembled by BMP1/tolloid proteinases [6],article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
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to the activin type IIB receptor (ActRIIB). Through
ActRIIB and its downstream effectors, particularly
Smad2/3, myostatin simultaneously activates protein
degradation and inhibits protein synthesis in adult
skeletal muscle [7, 8]. As a result, myostatin is a promising
therapeutic target for conditions of compromised muscle
health, including age-related sarcopenia, disease-associated
cachexia, congenital myopathies, muscular dystrophies,
disuse atrophy, and trauma.
Despite strong evidence that genetic and pharmaco-
logical modulations of myostatin abundance and/or ac-
tivity impact muscle mass in multiple species [9–13],
data on circulating myostatin concentrations in humans
are sparse and conflicting. In an early cross-sectional
study, serum myostatin levels measured by radio-
immunoassay (RIA) were reported to be significantly ele-
vated with advancing age and declining lean mass,
suggesting that myostatin may serve as a biomarker of
sarcopenia in women and men [14]. While provocative,
no subsequent study has been able to corroborate these
findings. Indeed, recent studies measuring concentra-
tions in the serum using enzyme-linked immunosorbent
assays (ELISAs) have reported either no change or a de-
cline in circulating myostatin levels in older compared
to younger persons [15–17]. Of further concern, ELISA-
based approaches for measuring circulating myostatin
concentrations have yielded highly erratic values for
healthy adults, ranging from just over 4 [15] to over 100
[18] and even 32,500 ng/ml [19].
The reasons for these inconsistent findings are not
clear but likely stem from the complexities of measuring
myostatin in clinical samples (reviewed in [20]). In
particular, some assays have not fully appreciated the
homology between myostatin and other circulating
TGF-β superfamily members, which can result in cross-
reactivity. For example, assays for myostatin may not
exclude GDF-11, which shares 90 % homology with
myostatin in its C-terminal biologically active domain
[21]. Lack of specificity has likely contributed to overes-
timates of serum myostatin levels in several previous
studies. The development and use of antibodies with
higher affinity and increased specificity for myostatin
have undoubtedly improved the accuracy of ELISA-
based approaches [15, 17]; however, these proprietary re-
agents remain unavailable to the broader research com-
munity. Antibody-based methods are also limited by
relatively low sensitivity. This is an additional challenge
to accurately quantify circulating myostatin, which is of
relatively low abundance in human serum. It is also
important to recognize that the earlier RIA study was
performed prior to the discovery that in circulation,
myostatin forms a latent complex when bound to its
inhibitory proteins, including follistatin-related gene(FLRG) protein and growth and serum protein-1
(GASP-1) [22, 23]. Only one study has provided insight
into how these proteins may change in relation to age,
muscle mass, and myostatin, and it was limited to men
[15]. Moreover, as reviewed above, the N-terminal
propeptide also inhibits myostatin activity. However,
current approaches used to measure circulating myosta-
tin concentrations are often unable to distinguish
between latent and mature forms. Collectively, these
methodological limitations have hindered progress in
understanding how myostatin may change in humans in
the context of health, aging, and disease and serve as a
biomarker for skeletal muscle mass.
To overcome these challenges, we developed a multi-
plexed assay combining immunoaffinity purification,
liquid chromatography with tandem mass spectrometry
(LC-MS/MS), and selected reaction monitoring (SRM)
to specifically and accurately measure tryptic peptides
from both the mature and propeptide regions of circu-
lating myostatin and two of its inhibitory proteins, FLRG
and GASP-1. We then applied this novel approach to a
well-characterized, population-based sample to determine
the extent to which circulating concentrations of myosta-
tin and its inhibitory proteins change within women and
men across adulthood, compare between women and
men, and associate with skeletal muscle mass.
Methods
Study subjects
Study subjects were selected from a random sample
of the population of Rochester, MN, USA, using the
Rochester Epidemiology Project medical records link-
age system as previously described [24]. A total of
240 subjects who met the study inclusion criteria
were studied, including 120 women and 120 men.
Within each sex, 40 younger (20–40 years old) and
80 older (≥65 years old) subjects were included. The
older women and older men were then each divided
into two groups of 40 subjects based on their relative
appendicular skeletal muscle mass (rASM). All 40 of
the older women and 34 of the older men with com-
paratively low rASM were below the cut-offs recently sug-
gested for sarcopenia, which are ≤5.67 and ≤7.23 kg/m2
for women and men, respectively [25]. The three groups
within each sex are herein referred to as younger, older,
and sarcopenic. The Mayo Clinic Institutional Review
Board approved this study, and all participants provided
written informed consent.
Subjects were rigorously screened for coexisting dis-
ease using clinical records, and a health history and
complete list of medications were obtained during an
interview. This study only included subjects without the
presence of coexisting disease and excluded postmeno-
pausal women on hormone replacement therapy but not
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medications associated with altered skeletal muscle mass
or function were also excluded. Menopause was defined
as the absence of menses for greater than 6 months.
Using this definition, all of the younger women were
premenopausal, whereas all older women were postmen-
opausal. All data, including serum samples, were col-
lected in the outpatient Mayo Clinical Research Unit
between November of 2000 and May of 2006. Blood
samples were collected from study subjects the morning
following an overnight fast and were stored at −80 °C.
Study protocol
Height was obtained (nearest millimeter) using a wall-
mounted stadiometer (Mayo Section of Engineering) and
weight obtained (nearest 0.1 kg) using an electronic scale
(Model 5002, Tronic, Inc., White Plains, NY, USA). Body
mass index (BMI, kg/m2) was calculated as the ratio of
weight to height squared. Total body and regional mea-
sures of lean mass (kg) and fat mass (kg) were obtained
from whole-body dual-energy X-ray absorptiometry
(DXA) scans (Lunar Prodigy, GE Medical Systems,
Madison, WI, USA), using software version 6.10.029.
The coefficient of variation (CV) for whole-body lean
mass (CV = 0.6 %) has been reported previously [26].
Grip strength (kg) and knee extensor strength (kg)
were assessed quantitatively with dynamometers (NK
Biotechnical Corp., Minneapolis, MN, USA). Estimates
of caloric expenditure (kcal/d) based on habitual levels
of physical activity over the preceding year were calcu-
lated using data obtained from a validated physical activ-
ity questionnaire [27] and were adjusted for body weight
as described previously [26]. Each activity was assigned a
published metabolic equivalent (MET [1 MET = 3.5 mL
O2 × kg
−1 × min−1]) value obtained from the compen-
dium of physical activities [28].
Materials
Tris(2-carboxyethyl)phosphine hydrochloride (TCEP)
and iodoacetamide were purchased from Sigma (St.
Louis, MO, USA). Phosphate buffered saline (PBS) was
purchased from Bio-Rad (Hercules, CA, USA). Ammo-
nium bicarbonate was purchased from J.T. Baker (Center
Valley, PA, USA). 3-[(3-cholamidopropyl)dimethylammo-
nio]-1-propanesulfonate (CHAPS), bovine serum albumin
(BSA), and trifluoroacetic acid (TFA) was purchased from
Thermo Fisher Scientific (Waltham, MA, USA). Zwitter-
gent Z3-16 was purchased from CalBiochem (EMD
Millipore, Billerica, MA, USA). Dynabeads® M-280 Strep-
tavidin was purchased from Invitrogen (Carlsbad, CA,
USA). Trypsin/Lys-C Mix was purchased from Promega
(Madison, WI, USA). Recombinant human myostatin
(cat# 4623–10) was purchased from Biovision (Milpitas,
CA, USA). Recombinant human GASP-1 (cat# 2070-GS-025), recombinant human FLRG (cat# 1288-F3-025),
biotinylated anti-myostatin antibody (cat# BAF788), bio-
tinylated anti-GASP1 antibody (cat# BAF2070), and
biotinylated anti-FLRG antibody (cat# BAF1288) were
purchased from R&D systems (Minneapolis, MN, USA).
Magnetic bead preparation
Biotinylated anti-myostatin, biotinylated anti-GASP-1,
and biotinylated anti-FLRG antibodies (0.25 μg/μL in
PBS with 0.1 % BSA) were each immobilized to Dyna-
beads® M-280 Streptavidin (10 mg/mL in PBS) at a ratio
of 40 μL antibody to 125 μL of magnetic bead suspen-
sion. These solutions were then combined, washed three
times with PBS, and reconstituted to a final volume of
625 μl with PBS.
Sample preparation
Standards, controls, and patient samples (400 μL) were
each transferred into 1.5-mL microcentrifuge tubes and
diluted with 600 μL PBS containing 0.03 % CHAPS. Fif-
teen microliters of the immobilized antibody mixture
(0.25 μg of each antibody) was added to each microcen-
trifuge tube containing sample or standards and incu-
bated overnight at 4 °C with rotation. The beads were
washed three times with 500 μL PBS, and the PBS was
removed before adding 15 μL of 8 M urea, 15 mM TCEP
in 50 mM ammonium bicarbonate. Synthetic internal
standard peptides were synthesized in the Mayo Proteo-
mics Core. Some target peptides were prepared as
extended tryptic sequence containing four to five add-
itional amino acids at both the N- and C-terminal ends to
take into account digestion efficiencies as noted in Table 1.
The internal standard peptide mixture (5 μM IIYGKI-
PAMV*VDRCGCS, 2.5 μM AGVLRADFPLSV*VRGH-
QAA, 12.5 μM GLPARLQVCGSD*G*ATYRDECEL, and
0.625 μM EQ*IIYGK, VSELTEE*PDSGR) in 50 mM am-
monium bicarbonate (5 μL) was added and the samples
incubated for 30 min at room temperature (RT). Follow-
ing reduction, samples were alkylated with 20 μL of
60 mM iodoacetamide (30 mM final) and incubated in
darkness for 30 min at RT. Subsequently, the urea was di-
luted to 1.1 M urea with the addition of 70 μL of 50 mM
ammonium bicarbonate. Finally, 5 μL of 0.2 μg/μL Tryp-
sin/Lys-C Mix was added directly to digest all bead bound
protein after incubation at 37 °C for 4 h. The digestion
was terminated by adding 5 μL of 4.7 % TFA with 0.02 %
Zwittergent® 3-16, and the digest was removed to an auto-
sampler vial after separation from the beads prior to LC-
MS/MS analysis.
Liquid chromatography-tandem mass spectrometry
LC-MS/MS was performed using a nanoAcquity UPLC
system (Waters Corporation, Milford, MA, USA) plumbed
with a vented tee and coupled to a TSQ Vantage triple
Table 1 Peptides, transitions, and instrument parameters for









IPAMVVDR 450.68 619.33 19 123
450.68 690.40 17 123
450.68 787.52 17 123
IIYGKIPAMV*VDRCGCS 453.65 619.44 19 123
453.65 690.50 18 123
453.65 763.65 16 123
EQIIYGK 425.66 480.31 13 86
425.66 593.47 14 86
EQ*IIYGK 429.14 480.35 13 86
429.14 600.43 14 86
Propeptide
TVLQNWLK 501.18 560.32 18 131
501.18 688.60 18 131
501.18 801.78 18 131
SIDVKTVLQNW*LKQPESN 504.75 567.25 19 131
504.75 695.42 17 131
504.75 808.65 15 131
ELIDQYDVQR 639.70 680.42 21 132
639.70 808.50 20 132
639.70 923.77 20 132
ELIDQYD*VQR 642.92 686.48 20 132
642.92 814.36 22 132
642.92 929.43 21 132
GASP-1
ADFPLSVVR 502.28 670.53 18 131
AGVLRADFPLSV*VRGHQAA 505.23 579.46 19 131
505.23 676.64 16 131
VSELTEEPDSGR 659.81 789.36 20 168
659.81 890.51 21 168
VSELTEE*PDSGR 662.73 795.31 21 168
662.73 896.60 21 168
FLRG
LQVCGSDGATYR 663.78 826.30 23 168
663.78 986.34 21 168
663.78 1085.46 21 168
GLPARLQVCGSD*G*ATYRDECEL
666.78 832.56 24 168
666.78 992.69 23 168
666.78 1092.15 22 168
Target peptides for each protein, parent and product ion masses as well as MS
parameters and transitions used quantitation of each protein are indicated in





15N-G, and 13C3-A) are indicated by the asterisk
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Jose, CA, USA) with an ADVANCE Captive Spray source
(Michrom Bioresources). Briefly, 10 μl of digested sample
was loaded onto a 0.25 μL OPTI-PAK® trap cartridge
(Optimize Technologies, Oregon City, OR, USA) packed
with Michrom Magic C8 (5 μm, 200 A) using 0.1 % formic
acid in 2 % ACN at a flow rate of 10 μL/min for 4 min.
Following loading, the peptides were eluted onto the ana-
lytical column (Michrom, Magic C18 AQ 200 A, 0.1 ×
150 mm, 3 μm) with a 20-min gradient from 98 % A
(0.1 % formic acid in 2 % ACN) to 40 % B (0.1 % formic
acid in 80 % ACN and 10 % IPA) at 1 μL/min. The gradi-
ent was taken to 95 % B in 3 min and held for 2 min at
95 % to wash the column. The column was then equili-
brated by returning the gradient to 98 % A in 3 min where
it was held for 7 min for a total run time of 35 min.
LC-MS/MS was performed in positive ion mode using
a spray voltage of 1400 V and a capillary temperature of
175 °C. All tryptic peptides and their corresponding la-
beled peptides were monitored in the (M + 2H+)2+
charge state. Transitions (Additional file 1: Table S1)
were monitored in three time segments. Resolution was
set at 0.7 FWHM for both Q1 and Q3. The scan time
was 20 ms, and the scan width was set at 0.05 Da.
Raw data analysis
Xcalibur Quan Browser version 2.2 was used for data
processing. Peak integration was performed with the fol-
lowing parameters: peak detection algorithm, genesis;
smoothing, 9; signal to noise threshold, 0.5. Peak areas
for each SRM transition were recorded individually, and
one transition per peptide was chosen for quantitation
(Additional file 1: Table S1). Peak area ratios were estab-
lished for each surrogate peptide and its corresponding
internal standard peptide, and calibration curves were
generated by plotting these ratios against protein con-
centration (nM). Each peptide was fit with a linear cali-
bration curve using 1/X weighting, with the exception of
VSELTEEPDSGR for GASP-1, which was fit with a
quadratic curve using 1/X weighting.
Other biochemical measures
Total 25-hydroxyvitamin D [25-(OH)D] (inter-assay CV =
7 %) was measured in serum using LC-MS/MS (API 5000;
Applied Biosystems-MDS Sciex, Foster City, CA, USA).
Total insulin-like growth factor 1 (IGF-1) and IGF-2
(inter-assay CVs = 6 % for both) were measured in serum
by a two-site immunoradiometric assay (IRMA), after sep-
aration from their binding proteins with a simple organic
solvent extraction (Diagnostic Systems Laboratories,
Webster, TX, USA). Serum insulin-like growth factor
binding protein 2 (IGFBP-2) (inter-assay CV = 16 %) was
measured by a double antibody RIA (Diagnostic Systems
Laboratories, Webster, TX, USA), whereas IGFBP-3
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site IRMA (Diagnostic Systems Laboratories, Webster,
TX, USA). Sex hormone-binding globulin (SHBG) (inter-
assay CV = 7 %) was measured in serum by RIA (Wien
Laboratories, Succasunna, NJ, USA) [29]. As described
previously [30], serum sex steroids, including estrone (E1,
inter-assay CV = 8 %), estradiol (E2, inter-assay CV = 8 %),
and testosterone (T, inter-assay CV = 6 %) were measured
using LC-MS/MS (API 5000; Applied Biosystems-MDS
Sciex, Foster City, CA, USA), which allows detection of
values as low as 1.25 pg/mL for both E1 and E2 and 1 ng/
dL for T. The non-SHBG bound (i.e., biologically active
fraction) of E2 and T (inter-assay CVs = 12 % for both)
were measured and then multiplied by the total E2 or T
measured by mass spectrometry to obtain the respective
bioavailable E2 and T fractions.
Statistical analysis
In women and men, separately, comparisons among the
younger, older, and sarcopenic groups were made using
an analysis of variance model. Comparisons between
younger, older and sarcopenic women, and the corre-
sponding group of men were made using an unpaired t
test. The Mann-Whitney U test was used when variables
were not normally distributed, as appropriate. Associa-
tions of myostatin levels with body composition, muscle
strength, physical activity, and other biochemical param-
eters were examined using age-adjusted Spearman corre-
lations. Testing was performed at a significance level of
P < 0.05 (two-tailed). Analyses were performed using
JMP 10.0 and SAS 9.3. Box plots (25–75 percentile), and
whiskers (Tukey method) were created using GraphPad
Prism 5.03.
Results
Validation of a LC-MS/MS assay for myostatin, GASP-1,
and FLRG
The peptides, transitions, and instrument parameters for
myostatin, propeptide, GASP-1, and FLRG are detailed
in Table 1. The lower limits of detection (LOD, average
blank concentration plus 3 SDs) for myostatin, propep-
tide, GASP-1, and FLRG were 0.01 (0.248), 0.015 (0.42),
0.01 (0.607), and 0.02 nM (0.258 ng), respectively. The
lower limits of quantification (LOQ, three replicates
<20 % CV within 20 % accuracy) for myostatin, propep-
tide, GASP-1, and FLRG were 0.01 (0.248), 0.015 (0.42),
0.01 (0.607), and 0.02 nM (0.258 ng), respectively. Stand-
ard curves for the proteins are presented in Fig. 1. The
intra-assay variability between five replicates of myosta-
tin, propeptide, GASP-1, and FLRG at four different
concentrations was less than 12, 10, 8, and 9 %, respect-
ively (Additional file 1: Table S1). The inter-assay
variability at different concentrations of myostatin, pro-
peptide, GASP-1, and FLRG was less than 21, 13, 11,and 8 %, respectively (Additional file 2: Table S2). The
percent recovery of myostatin, FLRG, and GASP-1
spiked into a pooled serum sample ranged from 65 to
88 % (Additional file 3: Table S3). Collectively, these data
validate a specific and sensitive LC-MS/MS method for
determination of even very low concentrations of mature
and propeptide forms of myostatin and two of its inhibi-
tors in human serum.
Clinical characteristics of the study subjects
Clinical characteristics of the younger, older, and sarco-
penic groups are shown in Table 2, and biochemical
parameters are shown in Table 3, stratified by sex. As
designed, sarcopenic older women and men had signifi-
cantly less lean mass (both relative appendicular skeletal
muscle mass (ASM) and total body lean mass (TBLM),
all p < 0.05) and lower grip and knee extension strength
than younger and older subjects of the same sex (all p <
0.05). Further, younger, older and older sarcopenic men
had greater lean mass (both relative ASM and TBLM; all
p < 0.001) than the corresponding group of women. In
fact, the sarcopenic older men not only had greater lean
mass than sarcopenic older women but also had greater
lean mass than both the younger and older groups of
women (Table 1). Consequently, in addition to using
absolute circulating myostatin concentrations in our
analyses, we calculated and used relative myostatin and
propeptide concentrations by normalizing to TBLM.
This facilitated interpretation of myostatin and propep-
tide concentrations within the context of a given amount
of lean mass.
Circulating concentrations of myostatin and myostatin-
related proteins in women and men
We first compared myostatin, propeptide, FLRG, and
GASP-1 within groups of women and men, separately.
Compared to younger women, older women had 33 %
higher circulating concentrations of myostatin (p < 0.001),
while sarcopenic older women had comparable levels
(Fig. 2a and Table 3). However, for a given amount of
TBLM, older women and sarcopenic older women had 40
and 23 % higher relative myostatin concentrations than
younger women, respectively (both p < 0.01; Fig. 2b). Simi-
lar patterns were observed for propeptide concentrations
(Table 3), namely, older women had 61 % higher absolute
concentrations of propeptide than younger women while
both older women and sarcopenic older women had 51
and 58 % higher relative propeptide levels than younger
women (Fig. 2c, d). There were no differences in the ratio
of myostatin to propeptide between the groups (data not
shown (DNS)). In contrast, younger men had significantly
higher absolute myostatin concentrations than older men
without or with sarcopenia (both p < 0.001; Fig. 2e and
Table 3). Of note, the age-associated decrease in
Fig. 1 Calibration curves for LC-MS/MS measures of myostatin, propeptide, GASP-1, and FLRG. Linear calibration curves for recombinant intact
myostatin (a), propeptide (b), GASP-1 (c), and FLRG (d) diluted into bovine serum albumin over a concentration range of 0.031 to 1.00 nM
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even after normalizing to TBLM, as younger men had at
least 25 % higher relative myostatin levels than both
groups of older men (both p < 0.01; Fig. 2f). Propeptide
levels were also significantly higher in younger men than
sarcopenic older men (Fig. 2g), but no differences were
observed between groups after normalizing propeptide
concentrations to TBLM (Fig. 2h and Table 3). Similar to
women, no differences in the ratio of myostatin to propep-
tide were observed among the groups of men.
We next explored circulating concentrations of two
inhibitors of myostatin, FLRG and GASP-1, in all sub-
jects. Compared to younger women, FLRG levels were
43 and 62 % higher in older women and sarcopenic
older women, respectively (both p < 0.001; Fig. 3a and
Table 3). GASP-1 changed in a like manner, but differ-
ences were only significant between younger women and
sarcopenic older women (p < 0.05; Fig. 3b). We next
assessed the ratios of FLRG to myostatin and GASP-1 to
myostatin. Sarcopenic older women had the highest
ratios of FLRG to myostatin compared to older and
younger subjects (Fig. 3c), while a modest decrease inthe ratio of GASP-1 to myostatin was observed in older
women compared to younger and sarcopenic older
women (Fig. 3d). Similar to women, circulating FLRG
concentrations were 68 % higher in older men and 64 %
higher in sarcopenic older men than in younger men
(both p < 0.001; Fig. 3e and Table 3), but trends for age-
associated increases in GASP-1 were not significant
(Fig. 3f ). Older men and sarcopenic older men had
higher ratios of both FLRG and GASP-1 to myostatin than
younger men (all p < 0.001; Fig. 3g, h, respectively). In
addition, sarcopenic older men had significantly higher ra-
tios of GASP-1 to myostatin than older men (p < 0.01).
Sex differences in circulating concentrations of myostatin
and myostatin inhibitors
In separate analyses, we compared myostatin, propep-
tide, FLRG, and GASP-1 concentrations in women to
those in the corresponding group of men. In all subjects
combined, circulating myostatin levels were 1.3-fold
higher in men than in women (median (interquartile
range (IQR)) = 7.8 (6.0–10.5) versus 6.0 (4.3–8.2) ng/mL,
p < 0.001), even after expressing myostatin relative to
Table 2 Descriptive characteristics of younger, older, and sarcopenic older women and men (n = 240)
Younger Older Sarcopenic
(n = 40) (n = 40) (n = 40)
Women
Clinical variables
Age (years) 32.3 ± 5.5 76.0 ± 8.6* 78.4 ± 8.2**
Weight (kg) 69.2 ± 17.4 78.2 ± 13.9* 68.1 ± 11.9***
Height (cm) 165 ± 6.3 160 ± 6.0* 160 ± 6.5**
BMI (kg/m2) 25.3 ± 5.9 30.6 ± 4.6* 26.7 ± 3.9***
Relative ASM (kg/m2) 5.9 ± 0.6 6.1 ± 0.7 4.9 ± 0.4**,***
TBLM (kg) 37.4 ± 3.9 37.9 ± 5.3 31.1 ± 3.3 **,***
TBLM/weight 0.56 ± 0.11 0.49 ± 0.07* 0.47 ± 0.07**
TBFM (kg) 28.2 ± 14.5 37.4 ± 10.4* 33.4 ± 9.7
TBFM/weight 0.38 ± 0.11 0.47 ± 0.07* 0.48 ± 0.07**
Muscle strength
Grip strength (kg) 27.5 ± 5.1 22.7 ± 5.1* 19.9 ± 3.4*****
Knee extensor strength (kg) 69.6 ± 16.9 52.7 ± 16.5* 42.9 ± 9.8*****
Physical activity
Energy expenditure (kcal/week) 30837 ± 7744 25399 ± 6125* 22645 ± 6451**
Men
Clinical variables
Age (years) 33.0 ± 3.8 74.8 ± 7.3* 78.9 ± 6.8**,***
Weight (kg) 92.3 ± 16.7 89.7 ± 15.6 75.9 ± 9.6**,***
Height (cm) 179 ± 5.8 175 ± 6.0* 171 ± 7.2**,***
BMI (kg/m2) 28.8 ± 4.7 29.2 ± 4.0 26.0 ± 2.4**,***
Relative ASM (kg/m2) 8.5 ± 1.0 7.9 ± 0.4* 6.7 ± 0.5**,***
TBLM (kg) 57.6 ± 7.3 54.7 ± 4.2 45.9 ± 4.9**,***
TBLM/weight 0.63 ± 0.08 0.62 ± 0.08 0.61 ± 0.07
TBFM (kg) 30.7 ± 12.0 31.6 ± 12.5 26.5 ± 7.3***
TBFM/weight 0.32 ± 0.08 0.34 ± 0.08 0.34 ± 0.06
Muscle strength
Grip strength (kg) 50.4 ± 9.5 39.2 ± 7.4* 33.7 ± 7.4**,***
Knee extensor strength (kg) 122 ± 33.7 80.7 ± 19.1* 61.7 ± 16.8**,***
Physical activity
Energy expenditure (kcal/week) 40136 ± 14350 34222 ± 9090* 27009 ± 7008**,***
Values are presented as mean ± SD and p values
BMI body mass index, ASM appendicular skeletal muscle mass, TBLM total body lean mass, TBFM total body fat mass
*p < 0.05 younger vs. older; **p < 0.05 younger vs. sarcopenic; ***p < 0.05 older vs. sarcopenic
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sus 9.7 (6.1–13.4)) and relative propeptide concentra-
tions were >1.3-fold higher in men than in women (both
p < 0.01). Among younger subjects, men had nearly two-
fold higher myostatin levels as compared to younger
women (p < 0.001) (Fig. 4a); this difference was dimin-
ished after expressing myostatin relative to TBLM
(Fig. 4b) but remained significant (p < 0.01). Similar
observations were made for propeptide, with younger men
having greater than twofold higher absolute concentrations(p < 0.001; Fig. 4c) and 42 % higher relative concentrations
than younger women (p < 0.05; Fig. 4d). In older subjects
and sarcopenic older subjects, no differences in absolute
myostatin or propeptide concentrations were observed be-
tween women and men (Fig. 4a and c, respectively). How-
ever, after adjusting for differences in TBLM, both older
women and sarcopenic older women had 52 and 14 %
higher relative myostatin levels than the corresponding
groups of men (p < 0.001 and 0.05, respectively; Fig. 4b).
Older women and sarcopenic older women also had 35
Table 3 Biochemical parameters in younger, older and sarcopenic older women and men (n = 240)
Younger Older Sarcopenic
(n = 40) (n = 40) (n = 40)
Women
Biochemical variables
Myostatin (ng/mL) 5.5 (3.2–7.3) 7.3 (5.7–11.7)* 5.3 (4.2–8.0)***
Myostatin/TBLM (ng/ml/kg) 0.142 (0.091–0.195) 0.199 (0.138–0.327)* 0.175 (0.145–0.255)**
Propeptide (ng/ml) 7.1 (5.2–10.8) 11.4 (7.3–20.1)* 10.0 (6.5–12.4)***
Propeptide/TBLM (ng/ml/kg) 0.194 (0.139–0.294) 0.292 (0.186–0.203)* 0.307 (0.203–0.417)**
FLRG (ng/mL) 5.1 (4.3–6.0) 7.3 (6.2–9.7)* 8.3 (6.7–10.6)**
GASP1 (ng/mL) 7.6 (6.5–10.1) 9.4 (7.2–11.0) 9.2 (7.1–12.2)**
Total 25-(OH)D (ng/mL) 25.0 (17.3–34.8) 20.0 (14.3–24.0)* 18.5 (14.0–24.8)**
IGF-1 (ng/mL) 235 (191–305) 141 (93–183)* 105 (78–147)**,***
IGF-2 (ng/mL) 1160 (958–1375) 1112 (933–1367) 1167 (884–1336)
IGFBP-2 (ng/mL) 406 (190–621) 447 (308–775) 635 (539–987)**,***
IGFBP-3 (ng/mL) 4580 (4099–5094) 4096 (3536–4513)* 3913 (3171–4389)**
Total E1 (pg/mL) 47.0 (33.3–57.8) 31.0 (19.0–37.0)* 23.0 (16.0–29.0)**
Total E2 (pg/mL) 54.0 (30.5–108.5) 5.6 (4.2–9.1)* 4.9 (3.2–7.3)**
Total T (ng/dL) 23.5 (18.0–30.0) 16.0 (12.0–24.0)* 21.0 (11.0–30.0)
Bio E2 (pg/mL) 15.0 (8.2–28.2) 2.1 (1.0–3.2)* 1.0 (0.6–1.7)**
,***
Bio T (ng/dL) 1.5 (0.9–2.1) 1.5 (1.0–2.6) 1.1 (0.7–1.8)***
SHBG (nmol/L) 63.1 (45.0–95.6) 40.5 (23.2–57.8)* 52.8 (46.7–73.0)***
Men
Biochemical variables
Myostatin (ng/mL) 10.5 (9.0–14.4) 7.1 (5.4–8.8)* 6.9 (4.4–8.9)**
Myostatin/TBLM (ng/ml/kg) 0.192 (0.156–0.241) 0.131 (0.101–0.164)* 0.153 (0.092–0.192)**
Propeptide (ng/ml) 15.7 (11.7–19.4) 11.8 (7.6–15.7) 10.8 (6.4–14.9)**
Propeptide/TBLM (ng/ml/kg) 0.276 (0.207–0.328) 0.216 (0.137–0.305) 0.240 (0.153–0.309)
FLRG (ng/mL) 4.5 (3.8–5.3) 7.5 (6.1–9.4)* 7.4 (6.3–9.9)**
GASP1 (ng/mL) 9.4 (7.5–10.6) 9.4 (7.3–10.7) 10.3 (8.9–11.9)
Total 25-(OH)D (ng/mL) 23.5 (17.0–31.8) 21.5 (17.0–25.8) 21.0 (16.0–26.8)
IGF-1 (ng/mL) 344 (292–446) 193 (114–245)* 169 (103–245)**
IGF-2 (ng/mL) 1099 (1005–1226) 961 (774–1075)* 964 (785–1071)**
IGFBP-2 (ng/mL) 244 (142–361) 547 (391–728)* 758 (531–1049)**
IGFBP-3 (ng/mL) 4469 (3833–4988) 3202 (2596–3581)* 3230 (2613–4019)**,***
Total E1 (pg/mL) 32.5 (25.3–38.0) 35.0 (30.0–45.0)* 31.0 (25.5–44.0)
Total E2 (pg/mL) 23.0 (19.0–30.0) 25.0 (20.0–28.0) 23.0 (18.0–29.0)
Total T (ng/dL) 462 (392–549) 424 (321–526) 484 (388–609)
Bio E2 (pg/mL) 12.8 (11.0–17.5) 9.5 (7.1–11.0)* 7.4 (5.5–10.0)**
Bio T (ng/dL) 133 (115–156) 50.8 (37.0–63.5)* 50.8 (37.4–62.7)**
SHBG (nmol/L) 25.1 (19.4–31.3) 45.5 (39.0–58.6)* 50.3 (39.9–64.0)**
Values are presented as median (IQR)
TBLM total body lean mass, FLRG follistatin-related gene protein, GASP-1 growth and serum protein-1, 25(OH)D 25-hydroxyvitamin D, IGF insulin-like growth factor,
IGFBP IGF-binding protein, E1 estrone, E2 estradiol, T testosterone; SHBG sex hormone-binding globulin
*p < 0.05 younger vs. older; **p < 0.05 younger vs. sarcopenic; ***p < 0.05 older vs. sarcopenic
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Fig. 2 Circulating myostatin and propeptide levels by LC-MS/MS in younger and older women and men. Box plots (25–75 percentile) and whiskers
(Tukey method) comparing serum concentrations of a myostatin, b myostatin relative to total body lean mass (TBLM), c propeptide, and d propeptide
relative to TBLM between younger women (YW), older women (OW), and sarcopenic older women (SOW). Comparisons of circulating concentrations
of absolute and relative concentrations of myostatin and propeptide between corresponding groups of men are also illustrated (e-h). *, **, and ***
denote p < 0.05, 0.01, and 0.001, respectively, compared to the younger group except when denoted with a bracket
Farr et al. Skeletal Muscle  (2015) 5:21 Page 9 of 16and 28 % higher propeptide levels relative to TBLM than
the corresponding groups of men (p < 0.01 and 0.05,
respectively; Fig. 4d).
Given the differences in myostatin levels between
women and men, we next examined whether circulating
concentrations of FLRG and GASP-1 differed. In youn-
ger, older, and sarcopenic older groups, FLRG and
GASP-1 levels were similar between women and men
(Fig. 5a, b, respectively). In younger subjects, the ratios
of FLRG and GASP-1 to myostatin were significantly
higher in younger women as compared to younger men
(both p < 0.001; Fig. 5c, d, respectively). In older and
sarcopenic older subjects, there were no differences
between women and men in the ratios of either FLRG
or GASP-1 to myostatin.
Associations between myostatin and body composition,
muscle strength, physical activity, and other circulating
biochemical parameters
We next examined associations between circulating
myostatin levels and body composition, muscle strength,
and physical activity using age-adjusted correlations inwomen and men, separately (Table 4). Positive albeit
weak correlations were observed between myostatin
concentrations and relative ASM and TBLM in women
and relative ASM in men (all p < 0.05). Moreover, in
men, a negative correlation was observed between myos-
tatin and total body fat mass (p < 0.05). Myostatin also
exhibited a significant correlation with grip strength
(p < 0.05) and a positive trend with knee extensor
strength (p = 0.073) in men but not in women. No
correlations were observed between concentrations of
myostatin and the amount of self-reported physical
activity. Finally, correlations between myostatin and
these clinical parameters are provided for the sub-
groups of younger, older, and older sarcopenic women
and men in Additional files 4: Table S4 and 5: Table
S5, respectively.
In women and men, myostatin levels exhibited modest
age-adjusted correlations with FLRG (both p < 0.01) and
stronger correlations with GASP-1 (both p < 0.001).
Analysis of other circulating biochemical parameters re-
vealed a negative correlation between myostatin and
total testosterone and sex hormone-binding globulin in
Fig. 3 Circulating FLRG and GASP-1 concentrations by LC-MS/MS in younger and older women and men. Box plots (25–75 percentile) and whiskers
(Tukey method) showing comparisons of a FLRG, b GASP-1, c FLRG relative to myostatin, and d GASP-1 relative to myostatin between younger
women (YW), older women (OW) and sarcopenic older women (SOW). Comparisons of myostatin inhibitors and their ratios to myostatin between
corresponding groups of men are also illustrated (e-h). *, **, and *** denote p < 0.05, 0.01, and 0.001, respectively, compared to the younger group
except when denoted with a bracket
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tatin had a positive association with bioavailable testos-
terone (p < 0.001, respectively). No correlations were
observed between myostatin and vitamin D or circulat-
ing components of the insulin-like growth factor (IGF)
system, including IGF-1, IGF-2, IGF-binding protein
(BP)-2, and IGFBP-3. Correlations between myostatin
and the biochemical parameters are provided for the
subgroups of younger, older, and older sarcopenic
women and men in Additional files 4: Table S4 and 5:
Table S5, respectively.
Discussion
In this study, we developed a highly specific and accur-
ate multiplexed LC-MS/MS assay for measuring circulat-
ing concentrations of mature and propeptide forms of
the muscle-derived protein, myostatin, and two of its in-
hibitors, FLRG and GASP-1, in human serum. Using this
novel approach and a well-characterized population-
based sample, we show that absolute and relative con-
centrations of myostatin and propeptide are higher in
younger men than younger women, increase with age inwomen, but in fact decrease with age in men. Intri-
guingly, these age-associated changes result in much
higher circulating myostatin and propeptide concentra-
tions per unit of lean mass in older women than older
men. We also demonstrate that circulating concentra-
tions of FLRG and, to a lesser extent, GASP-1 increase
similarly in women and men with age, particularly in the
context of sarcopenia. Finally, we report that circulating
concentrations of myostatin exhibit positive, but not ro-
bust, age-adjusted correlations with relative ASM in
both sexes.
As highlighted here and previously [31, 32], there are
several challenges to the specific and accurate measure-
ment of circulating myostatin concentrations using trad-
itional antibody-based approaches, such as RIA, ELISA,
and Western blotting. Through chromatographic separ-
ation and the use of peptide sequences, or “fingerprints,”
that are unique to and, in particular, distinct from GDF-
11, LC-MS/MS provides a highly specific method to
quantify myostatin. Using this approach, we observed
myostatin levels of 8.6 ± 3.7 ng/ml in men and 6.7 ± 3.3 ng/
ml in women. These concentrations are considerably lower
Fig. 4 Circulating myostatin and propeptide levels in women compared to men. Box plots (25–75 percentile) and whiskers (Tukey method)
showing comparisons of a myostatin, b myostatin relative to total body lean mass (TBLM), c propeptide, and d propeptide relative to TBLM
between younger women (YW) and younger men (YM) (top panel), older women (OW) and older men (OM) (middle panel), and sarcopenic OW
(SOW) and sarcopenic OM (SOM) (bottom panel). * and *** denote p < 0.05 and 0.001, respectively
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eral recent studies of healthy adults using commercial
ELISA kits [16, 18, 19, 33–35] but similar to the results ob-
tained in healthy adults using an ELISA comprised of pro-
prietary and presumably more specific, reagents ([15, 17].
In addition to improved specificity, LC-MS/MS has better
sensitivity for quantifying low abundance proteins than
antibody-based approaches. By coupling immunopurifica-
tion and LC-MS/MS, we observed both a LOD and a LOQ
of 0.01 nM, or 0.248 ng, for myostatin. In comparison,
Peiris et al. observed that the LOD for recombinantmyostatin proteins by Western blot was ~83.33 nM, or
2000 ng [32]. We established similarly low LOD and LOQ
values for propeptide, FLRG, and GASP-1. Therefore, this
novel multiplexed LC-MS/MS assay offers a highly specific
and sensitive means to quantify circulating concentrations
of myostatin and myostatin-related proteins in a single
small (400 ul) sample of human serum.
Myostatin is a promising therapeutic target to improve
muscle health [36]. Several pharmacological approaches
have been developed, including neutralizing antibodies,
propeptides, soluble decoy receptors, and receptor
Fig. 5 Circulating FLRG and GASP-1 concentrations in women compared to men. Box plots (25–75 percentile) and whiskers (Tukey method) showing
comparisons of a FLRG, b GASP-1, c FLRG relative to myostatin, and d GASP-1 relative to myostatin between younger women (YW) and younger men
(YM) (top panel), older women (OW) and older men (OM) (middle panel), and sarcopenic OW (SOW) and sarcopenic OM (SOM) (bottom panel). ***
denotes p < 0.001
Farr et al. Skeletal Muscle  (2015) 5:21 Page 12 of 16antagonists. Such interventions have been shown to in-
crease skeletal muscle mass and improve parameters of
strength and physical function in preclinical models of
aging and disease [12, 37, 38]. A number of early phase
clinical trials are underway [36, 39]. It is therefore sur-
prising then, that relatively little is known about the rela-
tionship between circulating myostatin concentrations
and skeletal muscle mass in human conditions associ-
ated with its loss or degeneration. Indeed such data
could inform the selection of indications or individuals
that may be most responsive to targeted interventions.In the present study, we demonstrate contrasting age-
associated changes in myostatin and propeptide levels in
women and men. Specifically, we observed higher abso-
lute and relative circulating concentrations in older
women compared to younger women and lower concen-
trations in older men compared to younger men. Unex-
pectedly, we also measured higher concentrations of
myostatin and propeptide per unit of lean mass in older
women and sarcopenic older women than in corre-
sponding groups of men. The prevalence of sarcopenia
is higher in women than men; however, we can only
Table 4 Age-adjusted Spearman correlations between
circulating myostatin levels and body composition, muscle
strength, physical activity and biochemical parameters in
women and men
Variable Women (n = 120) Men (n = 120)
r p value r p value
Body composition
BMI (kg/m2) 0.08 0.414 −0.11 0.250
Relative ASM (kg/m2) 0.24 0.010 0.24 0.008
TBLM (kg) 0.21 0.024 0.09 0.339
TBLM/weight −0.03 0.772 0.26 0.005
TBFM (kg) 0.05 0.585 −0.20 0.026
TBFM/weight 0.05 0.642 −0.27 0.003
Muscle strength
Grip strength (kg) 0.11 0.239 0.20 0.026
Knee extensor strength (kg) 0.12 0.211 0.17 0.073
Physical activity
Energy expenditure (kcal/d) −0.01 0.928 −0.08 0.376
Biochemical parameters
FLRG (ng/mL) 0.28 0.002 0.26 0.004
GASP1 (ng/mL) 0.53 <0.001 0.57 <0.001
Total 25-(OH)D (ng/mL) −0.04 0.701 −0.05 0.575
IGF-1 (ng/mL) −0.02 0.871 −0.06 0.515
IGF-2 (ng/mL) −0.17 0.072 −0.09 0.315
IGFBP-2 (ng/mL) −0.14 0.132 −0.07 0.439
IGFBP-3 (ng/mL) −0.15 0.115 −0.07 0.464
Total E1 (pg/mL) 0.03 0.777 0.09 0.309
Total E2 (pg/mL) 0.02 0.843 0.03 0.778
Total T (ng/dL) −0.20 0.027 0.18 0.056
Bioavailable E2 (pg/mL) 0.11 0.272 0.13 0.158
Bioavailable T (ng/dL) 0.12 0.188 0.32 <0.001
SHBG (nmol/L) −0.29 0.001 −0.13 0.170
Values are presented as Spearman correlation coefficients (r) and p values
BMI body mass index, ASM appendicular skeletal muscle mass, TBLM total
body lean mass, TBFM total body fat mass, FLRG follistatin-related gene protein,
GASP-1 growth and serum protein-1, 25(OH)D 25-hydroxyvitamin D, IGF i
nsulin-like growth factor, IGFBP insulin-like growth factor binding protein, E1
estrone, E2 estradiol, T testosterone, SHBG sex hormone-binding globulin
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associated muscle loss in women and that women may
be more responsive than men to anti-myostatin therap-
ies. In both sexes, we failed to see meaningful differences
in myostatin concentrations or the ratio of myostatin to
propeptide between older subjects and sarcopenic older
subjects. Of note, we studied healthy older persons with-
out chronic diseases associated with the deterioration of
skeletal muscle, including cancer, chronic heart failure,
chronic obstructive pulmonary disease, diabetes, chronic
kidney disease, and human immunodeficiency virus.
Future research is needed to determine the extent towhich myostatin concentrations, or the ratio of myosta-
tin to propeptide, are associated with skeletal muscle
mass and function in the context of such conditions.
In 1962, Bullough and Lawrence first proposed that
“diffusible substances,” or chalones, regulate the mass of
the specific tissue from which they were derived [1, 40].
Shortly after its discovery as a protein synthesized and
secreted by skeletal muscle, Lee and McPherron
highlighted the potential for myostatin to be a muscle
chalone [41]. As a chalone, myostatin may be an evolu-
tionarily conserved mechanism that was selected to pre-
vent the allocation of limited resources to the further
development and maintenance of the tissue from which
it is derived. In younger women, this may have been crit-
ical for reproduction. Consistent with the concept of an-
tagonistic pleiotropy, this early life benefit of myostatin
may have later life costs, namely, the excessive deterior-
ation of skeletal muscle. With the significant extension
in life expectancy beyond the menopause, it is plausible
that counter regulatory mechanisms could not be se-
lected for and, consequently, myostatin contributes to
the age-associated loss of skeletal muscle in women. In
men on the other hand, myostatin is highest in younger
men with the greatest muscle mass and, as would be an-
ticipated for a chalone, lowest in older men with the
least muscle mass. This same pattern is observed for
sclerostin, which is synthesized in and secreted by osteo-
cytes. Sclerostin functions as a potent negative regulator
of the Wnt/β-catenin signaling pathway to inhibit bone
formation [42]. Serum sclerostin levels are positively as-
sociated with total body bone mass in both women and
men [43]. The reason for sexually dimorphic age-related
changes in myostatin is unclear. We observed that FLRG
and GASP-1 are higher in younger women than younger
men and increase with age in both sexes and even more
so in those who are sarcopenic. This is the first report of
FLRG and GASP-1 serum concentrations in women;
however, in a smaller study using ELISAs, Ratvekius
et al. observed no differences or trends for a decrease in
FLRG and GASP-1 in older men compared to younger
men. Furthermore, our data fail to show meaningful re-
lationships between circulating myostatin concentrations
in women and established mediators of skeletal muscle
mass, including bioavailable testosterone, IGF-1, and
IGF-2. In men, we observed positive, not negative, asso-
ciations between circulating myostatin and bioavailable
estrogen and testosterone concentrations. Additional re-
search is needed to further understand what factors regu-
late myostatin abundance and/or activity and how such
factors are affected by aging in both women and men.
Our study provides important insights into age-related
changes and sex differences in the circulating concentra-
tions of myostatin and its related proteins in healthy
adults. However, it is important to recognize the cross-
Farr et al. Skeletal Muscle  (2015) 5:21 Page 14 of 16sectional design of our study. Longitudinal studies are
needed to better define the relationships between myos-
tatin, propeptide, FLRG and GASP-1 and age- and
disease-related changes in skeletal muscle mass and
performance, and the utility of these proteins as a bio-
markers of current and future muscle health. Our sam-
ple was also predominantly white, and underrepresented
with respect to persons of African, Asian, Hispanic,
Latino, American Indian, and Alaskan Native ancestry
groups. To our knowledge, the influence of origin on
myostatin concentrations has not been investigated. Fur-
thermore, our assay has notable strengths, including the
ability to precisely monitor four analytes in a single sam-
ple of merely 400 ul of serum. However, while we can spe-
cifically monitor the abundance of C-terminal (mature)
and N-terminal (propeptide) regions unique to myostatin,
at this time, we are not able to define the stoichiometry of
free (active) versus bound (latent) forms in vivo. Of note,
we did attempt an acid activation step in pooled serum to
overcome this hurdle; however, we had reduced recovery
of all proteins with the exception of propeptide, which did
not change. We therefore chose to immunoprecipitate
under physiological conditions without acid activation.
Even so, we believe this multiplexed LC-MS/MS approach
represents the current upper limit of specificity and sensi-
tivity for assessing myostatin, propeptide, FLRG, and
GASP-1 in human clinical samples, and that our study
represents the most comprehensive assessment of these
proteins in both women and men to date.
Conclusions
We have developed a highly specific and sensitive
LC-MS/MS-based method for measuring concentra-
tions of myostatin, propeptide, FLRG, and GASP-1 in
a single small volume of human serum. We propose
that (1) the age-associated increase in myostatin levels
in women may contribute to their lower muscle mass
and higher prevalence of sarcopenia relative to men;
(2) myostatin acts as a homeostatic regulator of
muscle mass in men, that is, the age-related loss of
muscle in men is coupled with a decrease in myosta-
tin and an increase in its inhibitors; (3) FLRG and
GASP-1 increase with age and in the context of sar-
copenia to inhibit the catabolic actions of myostatin;
and (4) circulating concentrations of myostatin pro-
vide a significant, albeit weak biomarker of muscle
mass in relatively healthy adult women and men. This
novel method will enable future studies to determine
the extent to which circulating concentrations of
myostatin and its inhibitors change in the context of
conditions associated with muscle loss or degener-
ation and, potentially, help identify individuals and
conditions that will best respond to therapies that
block myostatin signaling.Additional files
Additional file 1: Table S1. Intra-assay precision of five replicate
measures of recombinant myostatin, propeptide FLRG, and GASP-1 at
four concentrations diluted in 5 % bovine serum albumin in phosphate
buffered saline. A pooled human serum sample was also analyzed.
Additional file 2: Table S2. Inter-assay variability for immunoaffinity
purification and LC-MS/MS measures of recombinant myostatin, propep-
tide, FLRG, and GASP-1. Proteins were diluted together at the indicated
concentrations in 5 % bovine serum albumin in phosphate buffered sa-
line. Measures were performed five times over a period of 21 days. A
pooled human serum sample was analyzed similarly.
Additional file 3: Table S3. Percent recovery of myostatin, FLRG, and
GASP-1. A human serum pool was spiked (+) at two concentrations
(CONC) of the given analyte, and the percent recovery was determined
relative to the calculated value of the endogenous level plus the spiked
protein.
Additional file 4: Table S4. Spearman correlations between circulating
myostatin levels and body composition, muscle strength, physical activity,
and biochemical parameters in women.
Additional file 5: Table S5. Spearman correlations between circulating
myostatin levels and body composition, muscle strength, physical activity,
and biochemical parameters in men.
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